Brief: Theranexus Implements New Equity Line For Maximum Sum Of 4.2 Million Euros

Thx Pharma SA

13/01/2022 17:35

Jan 13 (Reuters) - Theranexus SA  ALTHX.PA :
    * IMPLEMENTATION OF A NEW EQUITY LINE
    * DECIDED TO IMPLEMENT A NEW EQUITY LINE FOR A TOTAL MAXIMUM
SUM
OF EUR4.2 M OVER 12 MONTHS THROUGH ISSUANCE OF WARRANTS ( "
WARRANTS ") FOR SUBSCRIPTION OF BONDS THAT CAN BE CONVERTED INTO
NEW SHARES IN COMPANY
    * THIS FUNDING AIMS TO PROVIDE THERANEXUS WITH ADDITIONAL
CAPACITY
TO SUPPORT ITS GROWTH. IN PARTICULAR, IT WILL HELP TO FINANCE
NEXT PHASES OF ITS CLINICAL DEVELOPMENT ON ITS BBDF-101 PROGRAM
IN BATTEN DISEASE
    * 1,680 WARRANTS WERE SUBSCRIBED IN FULL BY INVESTOR TODAY
    * INVESTOR WILL SUBSCRIBE TO BONDS UPON EXERCISE OF WARRANTS
IN 12
TRANCHES OF A NOMINAL VALUE OF EUR350,000 EACH BY 13 JANUARY
2023
    * AT ITS SOLE INITIATIVE AND WITHOUT FEES OR PENALTIES,
COMPANY
MAY SUSPEND OR REACTIVATE ISSUANCE OF BONDS OR TERMINATE
CONTRACT
    * BONDS WILL BE ISSUED AT NOMINAL VALUE WITHOUT DISCOUNT AT
INVESTOR'S INITIATIVE

Source text for Eikon:  ID:nACT72755 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))